Pharmacy & Therapeutics - October 2008 - (Page 606)

Medical Management of Parkinson’s Disease features of families with LRRK2-associated Parkinson’s disease. J Neural Transm Suppl 2006;(70):221–229. Mata IF, Wedemeyer WJ, Farrer MJ, et al. LRRK2 in Parkinson’s disease: Protein domains and functional insights. Trends Neurosci 2006;29(5):286–293. Electronic version, April 17, 2006. Nelson MV, Berchou RC, LeWitt PA. Parkinson’s disease. In: DiPiro JT, Talbert RL, Yee GC, et al., eds. Pharmacotherapy, A Physiologic Approach, 6th ed. New York: McGraw-Hill; 2005:1075– 1088. Jankovic J. Parkinson’s disease: Clinical features and diagnosis. J Neurol Neurosurg Psychiatry 2008;79:368–376. Kawahara K, Hashimoto M, Bar-On P, et al. Alpha-synuclein aggregates interfere with parkin solubility and distribution: Role in the pathogenesis of Parkinson’s disease. J Biol Chem 2008; 283(11):6979–6987. Fahn S. Parkinson’s disease and related disorders. In: Hazzard WR, Blass JP, Halter JB, et al., eds. Principles of Geriatric Medicine and Gerontology. New York: McGraw-Hill; 2003:1401–1408. Ahlskog JE. Parkinson’s disease: Medical and surgical treatment. In: Hurtig HI, Stern MB, eds. Neurol Clin Mov Disord 2001;19(3): 579–605. Michigan Parkinson foundation. Available at www.parkinsonsmi. org/facts.asp#5. Accessed September 12, 2008. Hirsch ML. Cognitive changes in Parkinson’s disease. American Parkinson Disease Association, 2008. Available at: www.wapark insons.org/edu_research/articles/Cognitive_Changes.html. Accessed May 3, 2008. Marsh, L. Not just a movement disorder: Cognitive changes in PD. Parkinson’s Disease Foundation, Winter 2007–2008. Available at: www.pdf.org/Publications/newsletters/winter07_08/Not_ Just_a_Movement.cfm. Accessed May 3, 2008. Galvin JE. Cognitive change in Parkinson disease. Alzheimer Dis Assoc Disord 2006;20:302–310. Standaert DG, Young AB. Treatment of central nervous system degenerative disorders. In: Hardman JG, Limbird LE, Molinoff PB et al., eds. The Pharmacological Basis of Therapeutics, 9th ed. New York: McGraw-Hill; 1996:503–519. Ahlskog JE, Muenter MD. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 2001;16:448–458. Stalevo, prescribing information, Novartis. Available at: www. pharma.us.novartis.com/product/pi/pdf/stalevo.pdf. Accessed April 2008. Ruottinen HM, Rinne UK. Entacapone prolongs levodopa response in a one-month double blind study in parkinsonian patients with levodopa-related fluctuations. J Neurol Neurosurg Psychiatry 1996;60:36–40. Frucht S, Rogers JG, Greene PE, et al. Falling asleep at the wheel: Motor vehicle mishaps in persons taking pramipexole and ropinirole. Neurology 1999;52:1908–1910. Parkinson Study Group. Pramipexole vs. levodopa as initial treatment for Parkinson’s disease: A randomized, controlled trial. JAMA 2000;284:1931–1938. Rascol O, Brooks DJ, Korczyn AD, et al. A five-year study of the incidence of dyskinesia in patients with early Parkinson’s disease who were treated with ropinirole or levodopa. 056 Study Group. N Engl J Med 2000;342:1484–1491. Ropinirole (Requip), prescribing information. GlaxoSmithKline, October 2006. Available at: http://us.gsk.com/products/ assets/us_ requip.pdf. Accessed September 9, 2008. Pramipexole (Mirapex), prescribing information, Boehringer Ingelheim. Available at: http://bidocs.boehringer-ingelheim.com. Accessed September 25, 2008. Haq IU, Lewitt PA, Fernandez HH. Apomorphine therapy in Parkinson’s disease: A review. Exp Opin Pharmacother 2007;8: 2799–2809. Apomorphine (Apokyn), prescribing information, Vernalis. Available at: www.drugs.com/pro/apokyn.html. Accessed September 25, 2008. Rotigotine Transdermal System (Neupro). Schwarz Pharma. Available at: www.schwarzpharma.com. Accessed May 5, 2008. Parkinson Study Group. Entacapone improved motor fluctuations in levodopa-treated Parkinson’s disease patients. Ann Neurol 1997;42:744–755. Erratum, Ann Neurol 1998;44:292. Kurth MC, Adler CH, Hillarie MS, et al. Tolcapone improved motor function and reduces levodopa requirement in patients with Parkinson’s disease experiencing motor fluctuations: A multimember, double-blind, randomized, placebo-controlled trial. Tolcapone Fluctuate Study Group 1. Neurology 1997;48:81– 87. Tolcapone (Tasmar), prescribing information, Valeant. Available at: www.valeant.com/fileRepositor y/products/PI/Tasmar_ PI_Feb_2006.pdf. Accessed September 15, 2008. Entacapone (Comtan), prescribing information, Novartis. Available at: www.pharma.us.novartis.com/product/pi/pdf/comtan. pdf. Accessed September 15, 2008. Olanow CW. MAO-B inhibitors in Parkinson’s disease. Adv Neurol 1993;60:666–671. Waters CH, Sethi KD, Hauser RA, et al. Zydis Selegiline Study Group. Zydis selegiline reduces off time in Parkinson’s disease patients with motor fluctuations: A 3-month, randomized, placebocontrolled study. Mov Disord 2004;19:426–432. Coelho M, Ferreira J, Sampaio C. Parkinson’s disease. In: Candelise L, Hughes R, Liberati A, et al., eds. Evidence-Based Neurology: Management of Neurological Disorders. Malden, MA: Blackwell Publishing; 2007. Chen JJ, Swope DM. Pharmacotherapy for Parkinson’s disease. Pharmacotherapy 2007;27:161S–173S. deMarcaida JA, Schwid SR, White WB, et al., and the Parkinson Study Group TEMPO and PRESTO Tyramine Substudy Investigators and Coordinators. Effects of tyramine administration in Parkinson’s disease patients treated with selective MAO-B inhibitor rasagiline. Mov Disord 2006;21:1716–1721. Olanow CW, Rascol O. Early rasagiline treatment slows UPDRS decline in the ADAGIO delayed-start study. Presented at the 133rd annual meeting of the American Neurological Association, Salt Lake City, Utah, September 21–24, 2008. Available at: www. abstracts2view.com/ana. Horn JR, Hansten PD. Preventing rasagiline drug interactions. Pharmacy Times 2007;73(1):80. Cogentin, adverse effects. WebMD. Available at: www.webmd. com/drugs/drug-279-Cogentin+Inj.aspx?drugid=279&drug name=Cogentin+Inj&pagenumber=6. Accessed September 15, 2008. Hallett PJ, Standaert DG. Rationale for and use of NMDA receptor antagonists in Parkinson’s disease. Pharmacol Ther 2004;102: 155–174. Amantadine (Symmetrel), prescribing information, Endo, 2003. Available at: www.endo.com/PDF/amantadine_pack_insert.pdf. Accessed September 16, 2008. Cantuti-Castelvetri I, Standaert DG. Neuroprotective strategies for Parkinson’s disease. Curr Neuropharm 2004;2:153–168. Parkinson Study Group. A controlled trial of rasagiline in early Parkinson disease: The TEMPO Study. Arch Neurol 2002;59: 1937–1943. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: Evidence of slowing of the functional decline. Arch Neurol 2002;59:1541–1550. Storch A, Jost WH, Vieregge P, et al. Randomized, double-blind, placebo-controlled trial on symptomatic effects of coenzyme Q10 in Parkinson disease. Arch Neurol 2007;64(7):938–944. Electronic version, May 14, 2007. Romano CJ. Levodopa and Parkinson’s disease progression: Contradictory results from the ELLDOPA study. Neurologyreviews. com, 2003:11(6). I 19. 20. 42. 43. 44. 45. 46. 21. 22. 23. 24. 25. 26. 47. 48. 49. 27. 28. 29. 50. 51. 52. 30. 31. 32. 53. 54. 55. 56. 57. 58. 33. 34. 35. 36. 37. 38. 39. 40. 41. 59. 606 P&T® • October 2008 • Vol. 33 No. 10 http://www.valeant.com/fileRepository/products/PI/Tasmar_PI_Feb_2006.pdf http://www.valeant.com/fileRepository/products/PI/Tasmar_PI_Feb_2006.pdf http://www.pharma.us.novartis.com/product/pi/pdf/comtan.pdf http://www.pharma.us.novartis.com/product/pi/pdf/comtan.pdf http://www.parkinsonsmi.org/facts.asp#5 http://www.parkinsonsmi.org/facts.asp#5 http://www.waparkinsons.org/edu_research/articles/Cognitive_Changes.html http://www.waparkinsons.org/edu_research/articles/Cognitive_Changes.html http://www.pdf.org/pdf/PDF_Winter_News-0708.pdf http://www.pdf.org/pdf/PDF_Winter_News-0708.pdf http://www.abstracts2view.com/ana http://www.abstracts2view.com/ana http://www.webmd.com/drugs/drug-279-Cogentin Inj.aspx?drugid=279&drugname=Cogentin Inj&pagenumber=6 http://www.webmd.com/drugs/drug-279-Cogentin Inj.aspx?drugid=279&drugname=Cogentin Inj&pagenumber=6 http://pharma.us.novartis.com/product/pi/pdf/stalevo.pdf http://www.webmd.com/drugs/drug-279-Cogentin Inj.aspx?drugid=279&drugname=Cogentin Inj&pagenumber=6 http://pharma.us.novartis.com/product/pi/pdf/stalevo.pdf http://www.endo.com/PDF/amantadine_pack_insert.pdf http://us.gsk.com/products/assets/us_requip.pdf http://us.gsk.com/products/assets/us_requip.pdf http://bidocs.boehringer-ingelheim.com http://www.drugs.com/pro/apokyn.html http://www.schwarzpharma.com

Table of Contents Feed for the Digital Edition of Pharmacy & Therapeutics - October 2008

Pharmacy & Therapeutics - October 2008 Contents Editorial Medication Errors Prescription: Washington New Drugs/Drug News/ New Medical Devices Drug Forecast Medical Management of Parkinson’s Disease Why Is Health Care Regulation So Complex? The Next President’s Prescription for Action on Drugs Trends in Managing Multiple Sclerosis Product Profiler: Sancuso®

Pharmacy & Therapeutics - October 2008

For optimal viewing of this digital publication, please enable JavaScript and then refresh the page. If you would like to try to load the digital publication without using Flash Player detection, please click here.